Edition:
United Kingdom

Avadel Pharmaceuticals PLC (AVDL.OQ)

AVDL.OQ on NASDAQ Stock Exchange Global Market

2.26USD
18 Dec 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.26
Open
$2.30
Day's High
$2.42
Day's Low
$2.22
Volume
43,551
Avg. Vol
39,798
52-wk High
$11.91
52-wk Low
$2.22

Latest Key Developments (Source: Significant Developments)

Broadfin Capital, LLC Reports An 8.4 Pct Stake In Avadel Pharmaceuticals As Of Dec 5
Tuesday, 11 Dec 2018 

Dec 11 (Reuters) - Avadel Pharmaceuticals PLC ::BROADFIN CAPITAL, LLC REPORTS AN 8.4 PERCENT STAKE IN AVADEL PHARMACEUTICALS AS OF DEC 5 - SEC FILING.BROADFIN CAPITAL, LLC SAYS PURHCASED AVADEL PHARMACEUTICALS' SHARES BASED ON BELIEF THAT THE SHARES WERE UNDERVALUED - SEC FILING.  Full Article

ASL Strategic Value Fund Says Avadel Pharmaceuticals Should Explore Sale
Wednesday, 28 Nov 2018 

Nov 28 (Reuters) - ASL Strategic Value Fund::ASL STRATEGIC VALUE FUND RELEASES LETTER TO AVADEL PHARMACEUTICALS BOARD OF DIRECTORS.ASL STRATEGIC VALUE FUND - FIRST CONTACTED AVADEL PHARMACEUTICALS' BOARD ON AUGUST 11.ASL STRATEGIC VALUE FUND - AVADEL PHARMACEUTICALS BOARD SHOULD IMMEDIATELY ADD SEVERAL NEW DIRECTORS, SELECTED BY MAJOR SHAREHOLDERS.ASL STRATEGIC VALUE FUND - AVADEL PHARMACEUTICALS SHOULD FORM SPECIAL COMMITTEE THAT SHOULD RETAIN AN INVESTMENT BANKING FIRM TO EXPLORE SALE OF CO.ASL STRATEGIC VALUE FUND - AVADEL PHARMACEUTICALS SHOULD EXPLORE BOTH SALE OR PARTNERING OF NOCTIVA.ASL STRATEGIC VALUE FUND - AVADEL PHARMACEUTICALS' BOARD SHOULD FORM SPECIAL COMMITTEE WITH MAJORITY OF NEW DIRECTORS SELECTED BY SHAREHOLDERS.  Full Article

Avadel Pharma Says Court Denied Preliminary Injunction Motion Regarding IP Litigation With Ferring Pharma
Friday, 9 Nov 2018 

Nov 9 (Reuters) - Avadel Pharmaceuticals PLC ::AVADEL PHARMA - COURT ISSUED OPINION & ORDER DENYING CO'S PRELIMINARY INJUNCTION MOTION REGARDING INTELLECTUAL PROPERTY LITIGATION WITH FERRING PHARMA.AVADEL PHARMACEUTICALS - AS RESULT OF COURT'S ORDER, FERRING IS NOT LEGALLY PRECLUDED FROM LAUNCHING ITS NOCDURNA PRODUCT.  Full Article

Avadel Pharma Receives Orphan Drug Designation From FDA For FT 218
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Avadel Pharmaceuticals Plc ::AVADEL PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION FROM FDA FOR FT 218 FOR THE TREATMENT OF NARCOLEPSY.  Full Article

Avadel Pharmaceuticals Issues 2018 Corporate Outlook
Friday, 29 Dec 2017 

Dec 29 (Reuters) - Avadel Pharmaceuticals Plc ::AVADEL PHARMACEUTICALS ISSUES 2018 CORPORATE OUTLOOK.REAFFIRMS FY 2017 ADJUSTED EARNINGS PER SHARE VIEW $0.25 TO $0.35.SEES FY 2018 REVENUE $110 MILLION TO $130 MILLION.SEES FY 2017 REVENUE $165 MILLION TO $175 MILLION.- ‍NDA FILING FOR FT218 EXPECTED BY YEAR-END 2018​.- COMMERCIAL LAUNCH FOR NOCTIVA ON TARGET FOR Q2 2018.FY2017 EARNINGS PER SHARE VIEW $1.48, REVENUE VIEW $171.8 MILLION -- THOMSON REUTERS I/B/E/S.AVADEL PHARMACEUTICALS- AV001 IS EXPECTED TO COMPETE IN AN ESTIMATED MARKET SIZE OF ABOUT $30 - $40 MILLION PER YEAR ONCE LAUNCHED IN 2019.- EXPECTS NEGATIVE CASH FLOW IN 2018.- ‍ASSESSING TAX CUTS AND JOBS ACT OF 2017 AND, ACCORDINGLY, IS UNABLE TO PROVIDE 2018 ADJUSTED DILUTED EPS GUIDANCE​.AVADEL PHARMACEUTICALS - ESTIMATES THAT PEAK REVENUES FOR NOCTIVA COULD BE AS HIGH AS $750 MILLION OR MORE PER YEAR.  Full Article